HMGCR and myocardial infarction: Third, all included studies were conducted prior to 2006; as standard treatment regimens for acute MI patients have changed substantially since then (e.g., revascularization with dual antiplatelet therapy, HMG CoA reductase inhibitors), the potential benefits of L-carnitine will need to be reassessed in the context of current treatment regimens that may affect the pharmacokinetics of L-carnitine.